Stockreport

Cyclacel Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Sapacitabine With Olaparib in BRCA Mutant Breast Cancer

Cyclacel Pharmaceuticals, Inc.  (CYCC) 
Last cyclacel pharmaceuticals, inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.cyclacel.com/investor-relations
PDF BERKELEY HEIGHTS, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC, Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutica [Read more]